Putting cash to work on significant market pullbacks such as the one that occurred Thursday is a key element of the strategy.
The good news is that this action is what is needed for much better opportunities in the future.
Amicus Therapeutics and Eiger BioPharmaceuticals set up well for using my covered call strategy.
Exelixis and Ultragenyx Pharmaceutical are cash rich mid-caps that don't look overbought.
The trading in hot sectors remains extremely bullish, but the action is shifting so quickly that many folks simply can't keep up.
UniQure NV and ProQR Therapeutics are companies based in Holland that have promising products in the pipeline.
Let's get out the magnifying glass and examine GNPX's selling of 4 million shares and the hit it took on Tuesday.
VERU's cancer drug Veru-111 was found to also be effective in treating Covid-19 patients in Phase II trials.
It's almost always better to sell into the greed of the market than trying to ride a greedy nag yourself.
ADMA Biologics and Organogenesis Holdings recently issued preliminary year-end 2020 results that were encouraging.